Prof. Crawford presents a pivotal study on the efficacy and safety of ponsegromab in patients with cancer-associated cachexia. He also highlights the RIVER-mPDAC study and the JMT203 study, both of which were presented at ESMO this year.
Prof. Aminah Jatoi presents three key studies from ESMO 2025. The first study examines indicators of cancer cachexia in patients with solid cancers. The second evaluates the efficacy and cost-utility of early oral nutritional supplementation in nasopharyngeal carcinoma undergoing chemotherapy and radiation. Additionally, she highlights the ponsegromab study presented by Prof. Crawford.